Cancer Therapy News and Research

RSS

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.

31 Mar 2014

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

A Canadian institution that annually recognizes seminal medical discoveries selected cancer immunotherapy leader Jim Allison, Ph.D., chair and professor of Immunology at The University of Texas MD Anderson Cancer Center, for one of its 2014 Canada Gairdner International Awards.

29 Mar 2014

Study: Sexual dysfunction common with lung cancer

Many lung cancer patients suffer difficulties with sexual expression and intimacy, yet for too long the topic has been ignored by doctors and researchers, experts have said at the 4th European Lung Cancer Conference (ELCC).

28 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

New era of lung cancer therapy close to dawning

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

27 Mar 2014

New approach could lead to devising alternative tools for cancer therapy

Inducing biological tissue damage with an atmospheric pressure plasma source could open the door to many applications in medicine

26 Mar 2014

Journal addresses impact of obesity on gynecologic cancer patients

Latest special issue of journal Gynecologic Oncology addresses the impact of obesity on gynecologic cancer patients, oncologists and cancer care delivery systems

26 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

Vigilant announces completion of $2 million oversubscribed Series A financing

Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.

25 Mar 2014

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Tampa, Fla., March 22-25.

25 Mar 2014

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Basic scientists focus on understanding how things work, so most don't get the chance to directly impact other people's lives. That's why Michelle Ozbun, PhD, is very excited about her recent grant to study human papillomavirus.

25 Mar 2014

Faster DNA sequencing techniques more likely to improve care for patients with breast cancer

Faster and cheaper DNA sequencing techniques will likely improve care for patients with breast cancer but also create challenges for clinicians as they counsel patients on their treatment options.

25 Mar 2014

ZL105 drug could potentially replace currently used anticancer drugs, study finds

A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates.

21 Mar 2014

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects but also improves a patient's life expectancy and quality of life.

20 Mar 2014

Study finds that health gap between survivors and their siblings widens with age

St. Jude Children's Research Hospital and the Childhood Cancer Survivor Study: Long-term follow-up of adult survivors of childhood cancer reinforces need for lifelong health surveillance for childhood cancer survivors

18 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

Researchers find effective strategy to eliminate cancer stem-like cells

Combining nanodrug-based chemotherapy and cryoablation provides an effective strategy to eliminate cancer stem-like cells (CSCs) the root of cancer resistance and metastasis, which will help to improve the safety and efficacy of treating malignancies that are refractory to conventional therapies.

14 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

The Medical University of South Carolina (MUSC), one of the nation's top academic health science centers, and Alliance Oncology, a division of Alliance HealthCare Services, Inc., announce a newly formed affiliation designed to strengthen and expand MUSC's Hollings Cancer Center as the radiation therapy market leader in Charleston, South Carolina.

12 Mar 2014

Oncologists use mathematical model to develop treatment plans for cancer patients

Physics applies to everything. So when Vittorio Cristini, PhD, started researching cancer, he applied physics. The result he got was a set of mathematical equations that describe, for each person, how many of their tumor cells a cancer treatment could kill.

12 Mar 2014

Cancer Therapy News and Research

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

Study: Sexual dysfunction common with lung cancer

Cytrx releases statement in response to two recent lawsuits

New era of lung cancer therapy close to dawning

New approach could lead to devising alternative tools for cancer therapy

Journal addresses impact of obesity on gynecologic cancer patients

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Vigilant announces completion of $2 million oversubscribed Series A financing

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Faster DNA sequencing techniques more likely to improve care for patients with breast cancer

ZL105 drug could potentially replace currently used anticancer drugs, study finds

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Study finds that health gap between survivors and their siblings widens with age

Trovagene reports net loss of $1 million for fourth quarter 2013

Researchers find effective strategy to eliminate cancer stem-like cells

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

Oncologists use mathematical model to develop treatment plans for cancer patients

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News